Early Intervention in Ulcerative Colitis: Ready for Prime Time?

被引:30
作者
Solitano, Virginia [1 ]
D'Amico, Ferdinando [1 ,2 ,3 ]
Zacharopoulou, Eirini [4 ]
Peyrin-Biroulet, Laurent [2 ,3 ]
Danese, Silvio [1 ,4 ]
机构
[1] Humanitas Univ, Dept Biomed Sci, I-20090 Milan, Italy
[2] Univ Lorraine, Univ Hosp Nancy, Dept Gastroenterol, F-54500 Vandoeuvre Les Nancy, France
[3] Univ Lorraine, Univ Hosp Nancy, Inserm NGERE U1256, F-54500 Vandoeuvre Les Nancy, France
[4] IRCCS, Humanitas Clin & Res Ctr, Dept Gastroenterol, IBD Ctr, I-20089 Milan, Italy
关键词
ulcerative colitis; early intervention; window of opportunity; top-down strategy; treat-to-target; INFLAMMATORY-BOWEL-DISEASE; EARLY RHEUMATOID-ARTHRITIS; ANTI-TNF THERAPY; CROHNS-DISEASE; RISK-FACTOR; COLORECTAL NEOPLASIA; NATURAL-HISTORY; DEEP REMISSION; TIGHT CONTROL; MANAGEMENT;
D O I
10.3390/jcm9082646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Growing evidence shows that ulcerative colitis (UC) is a progressive disease similar to Crohn's disease (CD). The UC-related burden is often underestimated by physicians and a standard step-up therapeutic approach is preferred. However, in many patients with UC the disease activity is not adequately controlled by current management, leading to poor long-term prognosis. Data from both randomized controlled trials and real-world studies support early intervention in CD in order to prevent disease progression and irreversible bowel damage. Similarly, an early disease intervention during the so-called "window of opportunity" could lead to better outcomes in UC. Here, we summarize the literature evidence on early intervention in patients with UC, highlighting strengths and limitations of this approach.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 63 条
  • [1] Moving towards disease modification in inflammatory bowel disease therapy
    Allen, Patrick B.
    Peyrin-Biroulet, Laurent
    [J]. CURRENT OPINION IN GASTROENTEROLOGY, 2013, 29 (04) : 397 - 404
  • [2] Balancing Benefit vs Risk of Immunosuppressive Therapy for Individual Patients With Inflammatory Bowel Diseases
    Beaugerie, Laurent
    Kirchgesner, Julien
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (03) : 370 - 379
  • [3] The Role of Early Biologic Therapy in Inflammatory Bowel Disease
    Berg, Dana Rachel
    Colombel, Jean-Frederic
    Ungaro, Ryan
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (12) : 1896 - 1905
  • [4] The Use of Prognostic Factors in Inflammatory Bowel Diseases
    Billiet T.
    Ferrante M.
    Van Assche G.
    [J]. Current Gastroenterology Reports, 2014, 16 (11) : 1 - 14
  • [5] Limited uptake of ulcerative colitis "treat-to-target" recommendations in real-world practice
    Bryant, Robert V.
    Costello, Samuel P.
    Schoeman, Scott
    Sathananthan, Dharshan
    Knight, Emma
    Lau, Su-Yin
    Schoeman, Mark N.
    Mountifield, Reme
    Tee, Derrick
    Travis, Simon P. L.
    Andrews, Jane M.
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (03) : 599 - 607
  • [6] Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn's disease - a SONIC post hoc analysis
    Colombel, J. -F.
    Reinisch, W.
    Mantzaris, G. J.
    Kornbluth, A.
    Rutgeerts, P.
    Tang, K. L.
    Oortwijn, A.
    Bevelander, G. S.
    Cornillie, F. J.
    Sandborn, W. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 41 (08) : 734 - 746
  • [7] Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
    Colombel, Jean Frederic
    Rutgeerts, Paul
    Reinisch, Walter
    Esser, Dirk
    Wang, Yanxin
    Lang, Yinghua
    Marano, Colleen W.
    Strauss, Richard
    Oddens, Bjoern J.
    Feagan, Brian G.
    Hanauer, Stephen B.
    Lichtenstein, Gary R.
    Present, Daniel
    Sands, Bruce E.
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2011, 141 (04) : 1194 - 1201
  • [8] Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
    Colombel, Jean-Frederic
    Panaccione, Remo
    Bossuyt, Peter
    Lukas, Milan
    Baert, Filip
    Vanasek, Tomas
    Danalioglu, Ahmet
    Novacek, Gottfried
    Armuzzi, Alessandro
    Hebuterne, Xavier
    Travis, Simon
    Danese, Silvio
    Reinisch, Walter
    Sandborn, William J.
    Rutgeerts, Paul
    Hommes, Daniel
    Schreiber, Stefan
    Neimark, Ezequiel
    Huang, Bidan
    Zhou, Qian
    Mendez, Paloma
    Petersson, Joel
    Wallace, Kori
    Robinson, Anne M.
    Thakkar, Roopal B.
    D'Haens, Geert
    [J]. LANCET, 2017, 390 (10114) : 2779 - 2789
  • [9] Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
    Colombel, Jean-Frederic
    Narula, Neeraj
    Peyrin-Biroulet, Laurent
    [J]. GASTROENTEROLOGY, 2017, 152 (02) : 351 - +
  • [10] Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
    D'Haens, Geert
    Baert, Filip
    van Assche, Gert
    Caenepeel, Philip
    Vergauwe, Philippe
    Tuynman, Hans
    De Vos, Martine
    van Deventer, Sander
    Stitt, Larry
    Donner, Allan
    Vermeire, Severine
    Van De Mierop, Frank J.
    Coche, Jean-Charles R.
    van der Woude, Janneke
    Ochsenkuehn, Thomas
    van Bodegraven, Ad A.
    van Hootegem, Philippe P.
    Lambrecht, Guy L.
    Mana, Fazia
    Rutgeerts, Paul
    Feagan, Brian G.
    Hommes, Daniel
    [J]. LANCET, 2008, 371 (9613) : 660 - 667